Cytek Biosciences reported second-quarter 2026 revenue of $48.1 million, a 5.5% year-over-year increase that missed analyst estimates by $0.51 million, while GAAP earnings per share of negative $0.09 came in-line with expectations. GAAP gross profit rose 19% to $28.3 million, with a gross margin of 59% compared to 52% a year ago, though excluding a one-time tariff refund the GAAP gross margin was 53%. Operating expenses increased 15% to $39.7 million, driven by higher research and development, sales and marketing, and general and administrative costs, resulting in a net loss of $12.2 million versus a net loss of $5.6 million in the prior-year quarter. The company updated its full-year 2026 revenue outlook to a range of $207 million to $212 million, raising the midpoint by $1 million. Cash, cash equivalents and marketable securities stood at $262.0 million as of June 30, 2026.
Cytek Biosciences IncQ2 revenue missed estimates and net loss widened, though EPS in-line and FY outlook raised slightly.
